Tags

Type your tag names separated by a space and hit enter

Formulation and in vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release.
Drug Dev Ind Pharm. 2008 Mar; 34(3):305-13.DD

Abstract

The emerging new fixed dose combination of metformin hydrocholride (HCl) as sustained release and glipizide as immediate release were formulated as a bilayer matrix tablet using hydroxy propyl methyl cellulose (HPMC) as the matrix-forming polymer, and the tablets were evaluated via in vitro studies. Three different grades of HPMC (HPMC K 4M, HPMC K 15M, and HPMC K 100M) were used. All tablet formulations yielded quality matrix preparations with satisfactory tableting properties. In vitro release studies were carried out at a phosphate buffer of pH 6.8 with 0.75% sodium lauryl sulphate w/v using the apparatus I (basket) as described in the United States Pharmacopeia (2000). The release kinetics of metformin were evaluated using the regression coefficient analysis. There was no significant difference in drug release for different viscosity grade of HPMC with the same concentration. Tablet thus formulated provided sustained release of metformin HCl over a period of 8 hours and glipizide as immediate release.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Mandal U
Bioequivalence Study Centre, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.
Pal TK
No affiliation info available

MeSH

Chemistry, PharmaceuticalDelayed-Action PreparationsDiabetes Mellitus, Type 2Drug CombinationsExcipientsGlipizideHypoglycemic AgentsHypromellose DerivativesMetforminMethylcelluloseSodium Dodecyl SulfateTabletsTechnology, PharmaceuticalViscosity

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18363146

Citation

Mandal, Uttam, and Tapan Kumar Pal. "Formulation and in Vitro Studies of a Fixed-dose Combination of a Bilayer Matrix Tablet Containing Metformin HCl as Sustained Release and Glipizide as Immediate Release." Drug Development and Industrial Pharmacy, vol. 34, no. 3, 2008, pp. 305-13.
Mandal U, Pal TK. Formulation and in vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release. Drug Dev Ind Pharm. 2008;34(3):305-13.
Mandal, U., & Pal, T. K. (2008). Formulation and in vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release. Drug Development and Industrial Pharmacy, 34(3), 305-13. https://doi.org/10.1080/03639040701657487
Mandal U, Pal TK. Formulation and in Vitro Studies of a Fixed-dose Combination of a Bilayer Matrix Tablet Containing Metformin HCl as Sustained Release and Glipizide as Immediate Release. Drug Dev Ind Pharm. 2008;34(3):305-13. PubMed PMID: 18363146.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Formulation and in vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release. AU - Mandal,Uttam, AU - Pal,Tapan Kumar, PY - 2008/3/26/pubmed PY - 2008/7/2/medline PY - 2008/3/26/entrez SP - 305 EP - 13 JF - Drug development and industrial pharmacy JO - Drug Dev Ind Pharm VL - 34 IS - 3 N2 - The emerging new fixed dose combination of metformin hydrocholride (HCl) as sustained release and glipizide as immediate release were formulated as a bilayer matrix tablet using hydroxy propyl methyl cellulose (HPMC) as the matrix-forming polymer, and the tablets were evaluated via in vitro studies. Three different grades of HPMC (HPMC K 4M, HPMC K 15M, and HPMC K 100M) were used. All tablet formulations yielded quality matrix preparations with satisfactory tableting properties. In vitro release studies were carried out at a phosphate buffer of pH 6.8 with 0.75% sodium lauryl sulphate w/v using the apparatus I (basket) as described in the United States Pharmacopeia (2000). The release kinetics of metformin were evaluated using the regression coefficient analysis. There was no significant difference in drug release for different viscosity grade of HPMC with the same concentration. Tablet thus formulated provided sustained release of metformin HCl over a period of 8 hours and glipizide as immediate release. SN - 0363-9045 UR - https://www.unboundmedicine.com/medline/citation/18363146/Formulation_and_in_vitro_studies_of_a_fixed_dose_combination_of_a_bilayer_matrix_tablet_containing_metformin_HCl_as_sustained_release_and_glipizide_as_immediate_release_ DB - PRIME DP - Unbound Medicine ER -